Wave Life Sciences (WVE) Operating Leases (2019 - 2026)
Wave Life Sciences' (WVE) quarterly Operating Leases came in at $40.1 million in Q2 2026, up 195.26% YoY from $13.6 million in Q2 2025, and up 442.6% on a QoQ basis from $7.4 million in Q1 2026.
Wave Life Sciences (WVE) Operating Leases (2019 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 8 years of Operating Leases data on file, last reported at $40.1 million in Q2 2026.
- Quarterly Operating Leases rose 195.26% year-over-year to $40.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $40.1 million (up 195.26% YoY) and the FY2025 annual result came in at $9.4 million, down 47.06% from the prior year.
- Operating Leases rose to $40.1 million in Q2 2026, from $7.4 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $40.1 million in Q2 2026 to a low of $7.4 million in Q1 2026.
- A 5-year average of $21.9 million and a median of $22.7 million in 2024 frame the typical range for Operating Leases.
- The widest YoY moves for Operating Leases: up 195.26% in 2026, down 52.99% in 2026.
- Tracing WVE's Operating Leases over 5 years: stood at $32.1 million in 2022, then decreased by 20.9% to $25.4 million in 2023, then sank by 30.07% to $17.8 million in 2024, then sank by 47.06% to $9.4 million in 2025, then jumped by 326.18% to $40.1 million in 2026.
- The last three Operating Leases figures came in at $40.1 million (Q2 2026), $7.4 million (Q1 2026), and $9.4 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.08 Mn |
| Mar 31, 2026 | 7.39 Mn |
| Dec 31, 2025 | 9.41 Mn |
| Sep 30, 2025 | 11.38 Mn |
| Jun 30, 2025 | 13.58 Mn |
| Mar 31, 2025 | 15.72 Mn |
| Dec 31, 2024 | 17.77 Mn |
| Sep 30, 2024 | 19.77 Mn |
| Jun 30, 2024 | 21.71 Mn |
| Mar 31, 2024 | 23.60 Mn |
| Dec 31, 2023 | 25.40 Mn |
| Sep 30, 2023 | 27.17 Mn |
| Jun 30, 2023 | 28.88 Mn |
| Mar 31, 2023 | 30.53 Mn |
| Dec 31, 2022 | 32.12 Mn |
| Sep 30, 2022 | 33.67 Mn |
| Jun 30, 2022 | 12.00 Mn |
| Mar 31, 2022 | 23.62 Mn |
| Dec 31, 2021 | 24.96 Mn |
| Sep 30, 2021 | 22.48 Mn |